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Galectin-3 is a member of the β-galactoside-binding lectin family, whose expression is 
often dysregulated in cancers. While galectin-3 is usually an intracellular protein found in 
the nucleus and in the cytoplasm, under certain conditions, galectin-3 can be secreted 
by an yet unknown mechanism. Under stressing conditions (e.g., hypoxia and nutrient 
deprivation) galectin-3 is upregulated, through the activity of transcription factors, such 
as HIF-1α and NF-κB. Here, we review evidence that indicates a positive role for galec-
tin-3 in MAPK family signal transduction, leading to cell proliferation and cell survival. 
Galectin-3 serves as a scaffold protein, which favors the spatial organization of signaling 
proteins as K-RAS. Upon secretion, extracellular galectin-3 interacts with a variety of 
cell surface glycoproteins, such as growth factor receptors, integrins, cadherins, and 
members of the Notch family, among other glycoproteins, besides different extracellu-
lar matrix molecules. Through its ability to oligomerize, galectin-3 forms lectin lattices 
that act as scaffolds that sustain the spatial organization of signaling receptors on the 
cell surface, dictating its maintenance on the plasma membrane or their endocytosis. 
Galectin-3 induces tumor cell, endothelial cell, and leukocyte migration, favoring either 
the exit of tumor cells from a stressed microenvironment or the entry of endothelial cells 
and leukocytes, such as monocytes/macrophages into the tumor organoid. Therefore, 
galectin-3 plays homeostatic roles in tumors, as (i) it favors tumor cell adaptation for 
survival in stressed conditions; (ii) upon secretion, galectin-3 induces tumor cell detach-
ment and migration; and (iii) it attracts monocyte/macrophage and endothelial cells to 
the tumor mass, inducing both directly and indirectly the process of angiogenesis. The 
two latter activities are potentially targetable, and specific interventions may be designed 
to counteract the protumoral role of extracellular galectin-3.
Keywords: galectin-3, cell signaling, migration, angiogenesis, tumor microenvironment
GALeCTiN-3 AND iTS KeY STRUCTURe TO FUNCTiON 
ReLATiONSHiPS
Besides the common sense that most of the biological information resides in both nucleic acid 
and amino acid sequences, glycans present either on the cell surface or in the extracellular matrix 
(ECM) molecules also constitute an important reservoir of biological information. The coding 
capacity of carbohydrates is much broader than DNA sequences and peptides due to the structural 
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and conformational diversity displayed by these molecules (1). 
This so-called “sugar code” collectively defines boundaries within 
tissues, thus serving as a constitutive territorial marker, besides 
indicating transient states of the cells present within these tissues. 
Different animal lectins, glycan-binding proteins, decipher the 
biological information imprinted in the “sugar code” and trig-
ger signaling pathways, orchestrating a variety of biological and 
pathophysiological processes.
Animal lectins are categorized into structurally related fami-
lies and superfamilies, based on highly conserved carbohydrate 
recognition domains (CRDs) (2). Within the lectin superfamilies, 
galectins constitute a family of animal lectins known to mediate 
a plethora of processes like cell adhesion, migration, survival, 
death, and differentiation. Initially termed S-type lectins, galec-
tins are a group of proteins expressed in all organisms. Galectins 
are characterized to bind β-galactose-containing glycoconjugates 
and share primary structural homology in their CRDs (3). This 
family, composed by 15 mammalian galectins, is classified in 
three subtypes or groups, namely (i) prototype, (ii) chimera, and 
(iii) tandem repeat group, according to the number and organiza-
tion of CRDs (4).
Galectin-3 is the only member of the chimera group (5). 
Galectin-3, initially known as Mac-2, ϵBP, CBP35, CB-30, and 
L29 among another names, is one of the best studied lectins and is 
constituted by three distinct domains: an NH2-terminal domain, 
a proline-rich collagen-α-like domain, and a COOH-terminal 
domain that contains the CRD (6). This protein is encoded by a 
single gene in humans (LGALS3) composed of five introns and six 
exons located in chromosome 14, locus q21–q22, and the protein 
has a molecular weight of ~31 kDa (7, 8). Its promoter region, 
as well as its first exon, exhibits a high content of CpG islands, 
indicating that epigenetic mechanisms also control galectin-3 
expression, as observed during malignant transformation and 
tumor progression (9).
Members of the galectin family bind simple β-galactosides, 
such as disaccharides or trisaccharides. However, this affinity is 
relatively weak compared to binding to natural glycoconjugate 
ligands expressed on cell surfaces or in the ECM. Galectin 
CRDs recognize different types of glycan ligands and show high 
affinity binding to different structures. Galectin-3 was originally 
described to bind preferentially to type 1 or type 2 Galβ1→3(4)
GlcNAc (N-acetyllactosamine) chains, and its affinity increases for 
polylactosamine structures and/or branched glycans over simple 
saccharides (10) (For more information, access “Consortium for 
Functional Glycomics,” Paradigm pages, accessed February 22, 
2016, http://www.functionalglycomics.org). However, specific 
binding of galectin-3 may be attenuated or enhanced, depending 
on the substituents that modify subterminal galactose residues 
in the galectin ligand. Accordingly, galectin-3 shows higher 
affinity to oligosaccharides bearing 2- or 3-O-α-substituents on 
the outer galactose residue of glycans, such as NeuNAcα2,3 lac-
tosamine or the A-blood group structure GalNAcα1,3 [Fucα1,2]
Galβ1,4GlcNAc (11). Additionally, sialylation and sulfation of 
glycoconjugates also interfere on the carbohydrate affinity and 
the specificity of galectins. For example, presence of 3′-O-sulfated 
or 3′-O-sialylated glycoconjugates increases the affinity toward 
galectin-8 (12). Otherwise, 6-O-α-substitution by sialic acid 
reduces galectin-3 carbohydrate affinity (13–16). Suzuki and 
colleagues have also demonstrated that pretreatment of H-ALCL 
cells with neuraminidase, which cleaves cell surface sialic acid, 
increases galectin-3 adhesion to integrins (17).
Carbohydrate-binding characteristics of galectins involve (i) 
the array of glycan ligands; (ii) the architecture, dynamics, and 
binding sites of CRDs; and (iii) the topological display of glycans. 
It has been suggested that differences in the amino acid properties 
of galectins are responsible for the different binding of glycans to 
the CRDs, since the 3D structure of the galectin CRDs have an 
almost identical fold, while their amino acid sequence identity 
is rather low (18–20). For example, the CRD of galectin-3 is 
30–40% identical with galectins 4–10 and 20–25% identical with 
galectin-1 and -2 (21–23). These differences provide specific 
structural features that determine carbohydrate-binding speci-
ficity. For example, galectin-3 has a higher affinity for GalNAc 
than galectin-1, due to an arginine residue at position 144 (23). 
The topological display of glycan ligands in glycoconjugates 
(glycoclusters) is also important to an appropriate spatial match 
between lectin domains and polyvalent ligands (24, 25). Upon 
binding, galectins may form supramolecular structures due to the 
formation of homodimers and multimers. Altogether, the bind-
ing characteristics of each galectin and their ability to form higher 
order complexes with their ligands will determine the biological 
functions ascribed to galectins.
The relationship between the quaternary structure and 
galectin-3 precipitation activity also provides information about 
its structure-bioactivity and binding properties. There are two 
mechanisms for the formation of oligomers of galectin-3; an 
N-terminal-dependent and a C-terminal-dependent association 
(26). The N-terminal-dependent association of galectin-3 was 
the first oligomerization mechanism described (27–30). In solu-
tion, monomeric galectin-3 is in equilibrium with oligomers and 
may precipitate as a pentamer in the presence of multivalent 
oligosaccharides (31–35). The N-terminal domains confer 
oligomer flexibility, making the overall oligomer highly flexible, 
which contribute to galectin-3 ability to dynamically convert to 
pentamers that form heterogeneous cross-linked complexes with 
specific multivalent glycoconjugates (33). The capacity of forming 
multivalent oligomers is responsible for the formation of lattices 
on plasma membranes, which contribute to stability and the bio-
logical functions of galectin-3 (36). This property of galectin-3 is 
targetable. For example, galectin-3C, a truncated form of human 
galectin-3, functions as an inhibitor of galectin-3 oligomerization 
and displays a more effective antitumor activity than the intact 
lectin (37–39).
Galectin-3 lattices are high-order supramolecular structures 
of the lectin cross-linked with its specific ligands. The most stud-
ied galectin-3 ligands are found in N-glycans from cell surface or 
ECM glycoproteins. The amount of N-glycan structures in a given 
glycoprotein determines the probability of lattice formation, 
which in turn interferes with biological aspects of the glycoprotein 
function, such as its endocytosis (receptor turnover) or its ability 
to transduce signals (40). Through its ability to form glycoprotein 
lattices, galectin-3 tunes the function of different receptors, such 
as the epidermal growth factor receptor, platelet-derived growth 
factor receptor, fibroblast growth receptor, vascular endothelial 
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growth factor receptor (VEGFR), and transforming factor-β 
receptor (40–42). It is worth noting that galectin-3 is not always 
associated with activation of endocytosis of glycoprotein recep-
tors. Indeed, a galectin-3-dependent lattice can lead to persis-
tence of a given receptor on the cell surface. For example, this 
observation suggests that galectin-3 does not directly determine 
the process of endocytosis but will be determined by the partners 
of the galectin-3 ligand on the cell surface.
Galectin-3 is widely distributed among different species and, 
at the cellular level, it can be found in the extracellular and intra-
cellular milieu (43–45). Hence, galectin-3 can participate in many 
important biological processes in the cytoplasm and nucleus, 
where no cognate carbohydrate ligands for galectin-3 are often 
present. These functions result from protein–protein interactions, 
showing the versatility of this molecule. Accumulating evidence 
shows that galectin-3 interacts with a large number of molecules. 
Based on the distribution of galectin-3 in different subcellular 
compartments and its ability to interact with different molecules, 
it has been suggested that galectin-3 serves as a shuttling protein 
(46), playing distinct roles in many biological processes depend-
ing on its localization. In the nucleus, galectin-3 modulates cell 
survival and mRNA splicing (47, 48). For example, galectin-3 
forms complexes with members of the spliceosome mediating 
pre-mRNA splicing and spliceosome assembly in a carbohydrate-
independent manner (49). Despite the absence of glycan ligands 
in intracellular compartment, electrostatic potential calculations 
show a linear array of three positively charged arginine residues 
in a cleft of galectin-3 CRD that suggests a possible binding site 
to RNA (23). In the same context, intracellular galectin-3 CRD 
modulates DNA damage response through interacting with 
BARD1, a BRCA1 partner (50), and attenuates the pro-apoptotic 
activity of Bax through interaction with members of the bcl-2 
family (51–55).
Galectin-3 undergoes posttranslational modifications, such as 
limited proteolysis and phosphorylation. Extracellular galectin-3 
may be cleaved by different molecules, such as matrix metallopro-
teases (MMPs) and the prostate-specific antigen (PSA). MMP-
dependent processing leads to its truncated form. As mentioned 
above, this truncated form of galectin-3 interferes with galectin-3 
multimerization and biological functions. Structural variants of 
galectin-3, due to single nucleotide polymorphisms or phospho-
rylation at specific sites of full galectin-3, interfere with prote-
olysis. There are three different single nucleotide polymorphisms 
in galectin-3 gene distributed in human populations (56,  57). 
For example, the change Pro64 for His64 has been associated 
with alterations in galectin-3 function and with breast (58) and 
prostate cancer (59) incidence. In fact, this P64H substitution is 
susceptible to MMP-2 and -9 cleavages (60).
Phosphorylation implicates conformational changes of the 
protein, altering the interaction of galectin-3 with ligands and 
its ability to participate in multivalent interactions (61–63). 
Although the physiological significance of this posttranslational 
modification remains unclear, it has been suggested that phospho-
rylation of galectin-3 may modulate its intracellular function and 
translocation. Galectin-3 may be phosphorylated at N-terminal 
Ser (Ser6 and Ser12) or at Tyr sites (61, 64–66). For example, 
serine phosphorylation has been associated with differential 
binding to laminin and mucin, besides playing a role in nuclear 
export and antiapoptotic activity of galectin-3 (67–69). Tyrosine 
phosphorylation of galectin-3, mediated by c-Abl kinase, appears 
to be essential for cell motility, lysosomal degradation, cleavage 
inhibition, and secretion of galectin-3 (58,  70, 71). However, 
the mechanisms involved in galectin-3 secretion and its traffic 
among different organelles in the intracellular compartment 
are not well-understood. Galectin-3 is unlikely to be secreted 
by the ER/Golgi pathway since it lacks the classical secretion 
signal sequence. In fact, few studies suggest alternative mecha-
nisms like vesicular release (72, 73), exosomes (74), and even a 
mechanotransduction-based mechanism (75) for its extracellular 
secretion. A conceivable possibility in pathophysiological condi-
tions, including cancers, is that part of extracellular galectin-3 
is released passively from dying cells. The basic mechanisms for 
galectin-3 subcellular compartmentalization have been partly 
unraveled. Galectin-3 lacks a nuclear localization sequence (NLS), 
and it interacts with components of the nuclear pore complex for 
its nuclear import–export (76–80). However, the fine control of 
galectin-3 translocation within subcellular compartments is not 
clearly understood.
Based on the aforementioned, it is not surprising that galec-
tin-3 is also involved in many pathological conditions like cancer. 
Indeed, the importance of carbohydrates and lectins in cancer 
biology can be illustrated by the specific glycosylation signatures 
found in human tumors (81–84). Besides multiple factors like 
availability and localization of nucleotide sugar donors and sub-
strates contributing to aberrant glycosylation in cancer, the main 
mechanism seems to be the differential expression of glycosyl-
transferases and glycosidases involved in the synthesis and catab-
olism of glycans (85). Besides changes in glycan sialylation, which 
interferes with galectin-3-binding as discussed above,  cancer 
cells often present a significant increase in beta1–6 branching in 
N-linked glycans due to increased MGAT5 (UDP-N-acetyl-d-
glucosamine: N-acetylglucosamine transferase V) activity (81, 82). 
MGAT5 overexpression is responsible to enhance metastasis 
potential in mouse mammary cancer cells (86). Canine mam-
mary tumor cells entering the blood stream accumulate a large 
amount of galectin-3, which is associated with emboli formation 
(15, 87). Besides altered glycosylation, galectin-3 expression is 
commonly dysregulated within the tumor microenvironment, 
either by altered expression in tumor cells or by its expression 
in infiltrating leukocytes [for a comprehensive list of studies in 
human tumors, see Ref. (88)].
GALeCTiN-3 iN CANCeR CeLL 
SiGNALiNG: A ROLe FOR GALeCTiN-3 
iN THe TUNiNG OF CeLLULAR STReSS 
SiGNALiNG PATHwAYS
It is well-documented that galectin-3 expression is altered 
in malignant tissues, and it has many functions in cancer 
progression, additionally the localization of this molecule is 
an important feature to understand its function, as already 
mentioned (84,  89). Here, we will discuss the involvement of 
galectin-3 in stress signaling pathways (MAPK family, from 
FiGURe 1 | Galectin-3 involvement in tumor progression. This figure represents the intra-and extracellular galectin-3 functions in processes like cell survival, 
migration, and angiogenesis. (A) In tumor cell, galectin-3 regulates signaling pathways like, Ras/Raf/MEK/ERK and Notch, modulating the cell survival, proliferation, 
and migration. Besides, NFκB and HIF positively regulate galectin-3 expression contributing to its function within the tumor microenvironment. (B) Extracellular 
galectin-3 promotes tumor cell migration through interaction with mediators, such as integrins and caveolin, leading to FAK stabilization. (C) Regarding 
angiogenesis, the full-length galectin-3 can form oligomers and bind to endothelial cell surface, preventing VEGFR and integrin internalization. In addition, galectin-3 
induces VEGF release by platelets. Furthermore, galectin-3 promotes monocyte/macrophage chemotaxis toward tumor microenvironment potentializing 
macrophage-induced angiogenesis. ECM, extracellular matrix. Red full arrows: galectin-3 contributes directly to pathway activation. Red dashed arrows: possible 
interaction of galectin-3 in described pathway.
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mitogen-activated protein kinase) and in the orchestration of 
both cell and tissue responses in stress conditions commonly 
found within the tumor microenvironment (Figure 1).
MAPKs are serine–threonine kinases that link extracellular 
signals with a diversity of cellular processes, such as growth, 
proliferation, migration, survival, and death (90). Abnormalities 
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in MAPK signaling play a key role in development and progres-
sion of cancer. MAPK family consists of three main groups (i) 
extracellular signal-regulated kinase (ERK), which is activated by 
the Ras–Raf–MEK cascade; (ii) p38; and (iii) c-Jun NH2-terminal 
kinase.
Galectin-3 was first associated with Ras signaling in can-
cers, as galectin-3 interacts selectively through its CRD with 
activated K-Ras (K-Ras-GTP) and stabilizes it in the “on” state 
(91). Activated K-Ras enhances the translocation of galectin-3 
to the plasma membrane and thereby galectin-3 increases 
K-Ras signaling, promoting phosphoinositide 3-kinase (PI3-K) 
activation and controlling both the intensity and duration of the 
K-Ras signal (Figure 1A). Through this mechanism, galectin-3 
and Ras regulate important processes in tumor cells, such as 
proliferation and survival, playing key roles in different cancer 
cells (e.g., breast cancer cells). Galectin-3 is necessary for optimal 
activation of K-Ras/MEK pathway in breast cancer cells (92). It 
has been proposed that high expression of galectin-3 cooper-
ates with K-Ras transforming activity, leading to the malignant 
phenotype. Additional data revealed that galectin-3 is an integral 
component of nanoclusters containing K-Ras, supramolecular 
structures partitioned into the plasma membrane. Formation of 
nanoclusters is essential for high fidelity signal transduction, with 
the ability to increase K-Ras activation to drive tumorigenesis via 
constitutive activation of Raf/MEK/ERK signaling cascade (93).
Galectin-3 is strongly expressed in thyroid carcinoma cells, 
but not in benign tumors, and as such, it is associated with the 
levels of GTP-bound K-Ras, thus contributing to thyroid carci-
noma malignancy. Furthermore, the disruption of the interaction 
between Ras/galectin-3 reduced ERK activation, enhanced the 
cell cycle inhibitor p21 expression, and inhibited proliferation 
in vitro and tumor growth in nude mice (94). Song and colleagues 
investigated the effects of galectin-3 in downstream signaling 
events to the Ras pathway, using complementary in  vitro and 
in  vivo systems in pancreatic carcinogenesis. These studies 
showed that galectin-3 downregulation leads to decreased activa-
tion of AKT and ERK; thus, decreasing cell invasion and reducing 
tumor growth in an orthotopic mouse model (95). Moreover, in 
2008, Saegusa and collaborators had reported that galectin-3 had 
an antiapoptotic role in keratinocytes treated with etoposide or 
irradiated with UVB light. In these experiments, keratinocytes 
devoid of galectin-3 were more susceptible to apoptotic stimuli 
by altered activation of ERK and reduced activation of AKT 
(96). The pro-survival role of intracellular galectin-3 and its 
association with the activation of Ras/Raf/MEK/ERK and the 
PI3-K/AKT pathways is now clear. Moreover, it has also been 
shown that galectin-3 enhances the migration of colon cancer 
cells (97) through activation of the K-Ras–Raf–ERK1/2 pathway 
(discussed below).
More recent studies have been carried out to understand the 
interaction of galectin-3 and downstream targets of the MAPK 
pathway. Gao and colleagues have investigated the roles and 
mechanisms of circulating galectin-3 in signal transduction, 
specifically in ERK signaling. Although intracellular galectin-3 
increased ERK phosphorylation through RAS activation, Gao 
found that exogenous galectin-3 may stimulate positively 
ERK1/2 in a calcium-sensitive and PKC-dependent manner. 
Using truncated proteins, they demonstrated that intact extra-
cellular galectin-3 is required to activate ERK1/2 in order to 
promote cell migration. In this study, AKT signaling was not 
activated by circulating galectin-3 (98). In another related study, 
it was observed that binding of galectin-3 to mucin 1 (MUC1), a 
mucin involved in potentiating growth factor-dependent signal 
transduction, enhances cell proliferation and motility in differ-
ent epithelial cancer cells, through activation of both ERK1/2 
and AKT pathways. Accordingly, galectin-3-depleted cells grew 
slowly as compared to the parental galectin-3-expressing cells 
(99). In sarcoma cells, galectin-3 disrupts focal adhesion plaques, 
inducing cell migration in an AKT-dependent manner (100).
There are few reports about galectin-3 and its relation with p38 
or JNK kinases (Figure 1A). Both kinases are more responsive 
to stress stimuli than growth factors, comparing with ERK1/2. 
Thus, when Borges and collaborators investigated the effect of 
copper complexes in melanoma cells, they demonstrated that 
the metal treatment increased the levels of intracellular reactive 
oxygen species (ROS), which was accompanied by p38 activation 
in galectin-3-expressing melanoma cells (101). In addition, it 
has been reported that extracellular galectin-3 induces MMP-9 
expression via p38 MAPK pathway in melanoma cells (102). These 
results show a different function of galectin-3 in p38 regulation, 
associated with another critical circuitry of the malignant pheno-
type, invasion, and metastasis. Regarding the JNK kinase family, 
it is known that intracellular galectin-3 activates elements of the 
JNK pathway. Evidence exists that the activation of both ERK and 
JNK1/2 depend on the phosphorylation status of the Ser6 residue 
of galectin-3. Phosphorylation of galectin-3 by kinases, such as 
casein kinase, seems necessary to the activation of antiapoptotic 
circuits dependent on ERK and JNK (68). Although it is known 
that galectin-3 regulates the activity of MAPK pathway in several 
cancer models, further studies are still necessary to elucidate 
the mechanistic details of the pro-survival activity of galectin-3. 
These studies will be necessary to design targeting strategies for 
potential clinical interventions.
Galectin-3 expression is Regulated by 
Both NF-κB and HiF
NF-κB is a family of transcription factors that plays important 
roles in the immune system and regulates the expression of 
cytokines, cyclo-oxygenase 2 (COX-2), growth factors, and 
inhibitors of apoptosis. Moreover, pathological dysregulation of 
NF-κB is associated with inflammatory and autoimmune diseases 
as well as cancer (103). On studying galectin-3 expression in 
glioblastoma cells exposed to a variety of stressing stimuli, Dumic 
and colleagues found that NF-κB inhibition by specific protea-
somal inhibitors decreased the expression of galectin-3 (104). 
In the same way, it was also showed that the interference in NF-κB 
activation can inhibit galectin-3 expression leading to apoptotic 
processes (105). We have found a relationship among galectin-3, 
NF-κB, hypoxia and nutrient deprivation, and common stressing 
conditions within the tumor microenvironment. HIF-1α is a 
master regulator of gene transcription under hypoxia, upregu-
lating several genes, including galectin-3, in order to maintain 
cellular homeostasis and promote cell survival in skeletal tissues 
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(106). At the tissue level, galectin-3 accumulates in hypoxic/
nutrient-deprived areas from both glioblastoma and mammary 
tumors (87, 107–109). Under hypoxic conditions, galectin-3 
transcription requires protein synthesis and depends on both 
HIF-1α and NF-κB activities (Figure 1A). Nuclear translocation 
of NF-κB was also induced within hypoxic/nutrient-deprived 
microenvironments, such as pseudopalisades in glioblastomas 
(109). Such areas are enriched in galectin-3, which protects cells 
from death. More recently, another study has shown that galectin-3 
deficiency reduces proliferation of hepatoma cells and increases 
their rate of apoptosis both in  vitro and in  vivo. Conversely, it 
was demonstrated that galectin-3 expression induced by NF-κB 
transactivation led to a more invasive phenotype of tumor cells, 
which developed larger tumors as compared to those found in 
galectin-3−/− mice (110).
Galectin-3 and Notch Signaling
Notch signaling plays a key role in differentiation, survival, 
and/or proliferation. Alterations in the regulation of these 
processes contribute to malignant transformation – abnormal 
activation of this pathway is often found in various types of 
cancers. Notch signaling pathway involves communication 
among adjacent cells, one expressing a ligand (either Delta or 
Jagged) and the other expressing Notch, as a receptor and sig-
nal transducer (111). Initially, it was described that  galectin-1 
increased the expression of Notch1/Jagged2, promoting lung 
cancer progression (112). Fermino and collaborators then 
showed that endogenous galectin-3 selectively regulates 
downstream targets of Notch signaling pathway. Cells devoid 
of galectin-3 displayed a higher expression of Notch and its 
target gene HES-1 in an infection model (113). Nakajima and 
colleagues had described a galectin-3-dependent activation of 
Notch1 signaling in a system that models tumor cell/osteoblast 
and osteoclast interactions, critical events in the maintenance 
of bone metastasis found in different cancers, such as breast and 
prostate cancers. Using coculture of human fetal osteoblasts 
(hFOB) with cancer cells expressing galectin-3, these authors 
showed that galectin-3 secreted by cancer cells inhibited osteo-
blast differentiation, a Notch1-regulated process. Extracellular 
galectin-3 interacted with Notch1, in a CRD-dependent man-
ner, activating Notch through its proteolytic cleavage, which 
leads to the formation of Notch intracellular domain (NICD) 
with its subsequent translocation to the nucleus leading to 
Notch target genes upregulation (Figure 1A), which in turn is 
associated with the maintenance of a non-differentiated state 
of the osteoblast. In this set of experiments, Nakajima and col-
leagues also evaluated both intact galectin-3 and a truncated 
form of galectin-3 containing primarily its CRD. Although both 
forms of galectin-3 led to the activation of Notch, results shown 
apparently indicate that the intact galectin-3 is more efficient 
in the induction of Notch cleavage than its truncated form. 
Altogether, these events promoted suppression of osteoblast 
differentiation and caused bone remodeling in bone metastatic 
lesions (114). These experiments open a venue for research in 
a variety of Notch-dependent processes, from maintenance 
of a non-differentiated state of cells/tumor cells, activation of 
survival pathways, which in turn lead to resistance to different 
therapeutic strategies, to the process of angiogenesis.
GALeCTiN-3 PROMOTeS TUMOR 
MiGRATiON
Tumor progression is dictated by the bidirectional interaction 
between tumor and host cells that compose the tumor microenvi-
ronment. Besides that, it is also true that the ECM is an important 
non-cellular component of the tumor microenvironment that 
interferes with tumor initiation and progression. Based on the 
fact that galectin-3 can be secreted by cells (either actively or 
passively) and acts in the extracellular environment either as a 
monomer or a multimer, forming complexes with other mol-
ecules, one might expect that, upon interaction with its specific 
partners, galectin-3 interferes with different aspects of cancer cell 
behavior. Here, we will present some examples of how galectin-3 
coordinates cellular responses in two critical hallmarks of cancer, 
tumor cell motility (see Galectin-3 Promotes Tumor Migration) 
and angiogenesis (see Galectin-3 in Tumor Vasculature).
Recently, Shetty and colleagues observed that galectin-3 
promotes cell migration through its association with annexin 
A2 (AnxA2) on the plasma membrane of HER-2 negative breast 
cancer cells. This effect was abrogated by tunicamycin, an inhibi-
tor of N-linked glycosylation, and chickpea lectin, a plant lectin 
highly specific for N-acetyl-d-galactosamine of AnxA2, showing 
that this migratory effect is dependent on galectin-3 CRD domain 
(115). To gain some insight regarding galectin-3 extracellular 
function on cell migration, Gao et al. (98) showed that exogenous 
galectin-3 promoted HeLa cell migration through the activation 
of ERK 1/2 via a calcium-sensitive and PKC-dependent pathway, 
which was not abrogated by endogenous galectin-3 knockdown. 
Moreover, the authors observed that this phenomenon was 
dependent on both CRD and N-terminal domain of galectin-3. 
In this context, a specific peptide targeting galectin-3 was able to 
inhibit prostate cancer cell migration, raising the possibility that 
galectin-3 inhibitors might avoid tumor spread (116).
Regarding galectin-3 migratory effect, it has been reported 
that galectin-3 silencing leads to a decrease in cell migration 
and invasion, through the regulation of different intracellular 
molecules. In osteosarcoma, this phenomenon was accompa-
nied by a reduction in β-catenin expression and activation of 
important mediators of migration and invasion, such as FAK, 
Src, and Lyn  (117). In human tongue cancer cell lines as well 
as pancreatic cell lines, the reduction of migration and invasion 
leads to a decrease in β-catenin, phospho-Akt, GSK-3β, and 
some MMP levels, indicating that galectin-3-mediated migra-
tion and invasion involves β-catenin degradation initiated by 
Akt phosphorylation in this model (118). In sarcoma cells, a 
similar trend was observed, as sarcoma cells devoid of galectin-3 
were rendered more migratory when exposed to extracellular 
galectin-3, in a process dependent on the phosphorylation of 
AKT (100). Other study also indicated the correlation between 
urokinase-type plasminogen activator receptor (uPAR) levels 
and galectin-3-decreased migration in hepatocellular carcinoma 
cells (119). Likewise, Wu et al. (97) showed that overexpression 
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of galectin-3 in colon cancer cells induced cell migration, which 
was correlated with lung colonization in a mouse model.
Again, in a metastatic murine melanoma cell line, B16F10, 
knocking down of galectin-3 reduced cell migration and invasion 
as well as MMP-1 levels (120). In vivo, low levels of galectin-3 in 
B16F10 cells caused a reduction in number of lung metastatic 
nodules. The authors investigated the molecular mechanism 
behind this biological effect and found that galectin-3 interacts 
with the transcriptional factor AP-1, promoting its binding to 
MMP-1 promoter driving the transcription of this metallopro-
teinase. In addition, it was also demonstrated that reduced levels 
of galectin-3 inhibited the binding of both transcription factors 
c-jun and fra-1 to the promoter sites of MMP-1. The interaction 
of intracellular galectin-3 and AP-1 was also described a year 
earlier in gastric cancer (121). In this study, the authors showed 
that the complex formed by galectin-3 and AP-1 binds to PAR-1 
promoter driving its transcription, which was essential for 
galectin-3-mediated cell migration and invasion. Moreover, the 
role of MMP-1 in this phenomenon was pointed out, since its 
silencing caused a decrease in galectin-3-mediated cell migration.
Galectin-3 also regulates tumor cell migration through 
other mechanisms (Figure 1B). Exogenous galectin-3, through 
its ability to form lattices on the cell surface, restored FAK 
stabilization and cell motility in galectin-3 knockdown cancer 
cells (122). Lattice formation depends on the density of the 
glycosylated galectin-3 ligands found on the membrane and on 
the state of multimerization of galectin-3. Lattices form spatial 
plasma membrane subdomains, and together with lipid rafts 
and caveolin-dependent domains, are crucial for the spatial 
organization of signaling molecules. For example, galectin-3 and 
phosphorylated caveolin-1 act synergistically to promote EGF-
induced RhoA activation and Mgat 5+/+ cell migration (123). The 
intracellular phosphorylated form of caveolin-1 activates focal 
adhesion kinase (84). Boscher and Nabi (123) observed that 
EGF promoted MDA-MB-231 breast cancer cell migration in a 
phosphocaveolin-1 and galectin-3-dependent manner, enabling 
the metastatic spread of these cells.
Additionally, it was demonstrated that the synergistic action 
of galectin-3 and caveolin-1 induced focal adhesion turnover and 
migration of differentiated thyroid cancer cells (124). Galectin-3 
also promotes the raft-dependent endocytosis of integrins and 
plays a role in cell–matrix interaction (123). In this context, a 
novel function of galectin-3 has been reported related to the 
regulation of cell surface receptors by constitutive endocytosis. 
Specifically, Lakshminarayan and colleagues showed that both 
glycosphingolipids and extracellular galectin-3 mediate clathrin-
independent carriers (CLICs)-dependent endocytosis. This work 
also reported that galectin-3 is critical for CD44 and β1-integrin 
endocytosis (125). In an intracellular context, Liu and collabora-
tors reported that the absence of galectin-3 impairs keratinocyte 
migration, and this phenomenon was associated with the func-
tion of galectin-3 in the control of intracellular trafficking and cell 
surface expression of EGFR after EGF stimulation (126). Recently, 
another study demonstrated that galectin-3 knockdown potenti-
ates the response to gefitinib (EGFR-tyrosine kinase inhibitor) 
treatment in esophageal squamous cancer cells, a type of cancer 
that overexpresses EGFR. The absence of galectin-3 impairs 
the EGFR endocytosis, which enhanced the antitumor effect in 
gefitinib-insensitive cells like cell viability, cell cycle, and inva-
sion (127). Otherwise, Mazurek and collaborators observed that 
the silencing of galectin-3 restores tumor necrosis factor-related 
apoptosis-inducing ligand (TRAIL) sensitivity and promotes 
TRAIL-mediated endocytosis of TRAIL/death receptors. Thus, 
galectin-3 impairs TRAIL trafficking by anchoring them in cell 
membrane surface and blocks the execution of the apoptosis 
signal (128). Therefore, through regulation of endocytosis and 
intracellular trafficking of glycoproteins like integrins, galectin-3 
assumes a novel role in the control of tumor cell adhesion and 
migration.
GALeCTiN-3 iN TUMOR vASCULATURe
The successful growth of a tumor mass – either a primary tumor 
or its metastasis – requires the establishment of an adequate blood 
supply, frequently, but not exclusively, achieved by the formation 
of new blood vessels. From premalignant to malignant lesions, the 
transition between an avascular to a vascular phase is required. 
Such transition is dictated by the balance of pro- and antiangio-
genic signals. Therefore, the angiogenic switch activation requires 
the secretion of proangiogenic factors produced by both tumor 
and stromal cells within the tumor microenvironment (129).
Angiogenesis is characterized by a series of endothelial cell 
responses to this angiogenic balance, which include ECM degra-
dation and budding, proliferation, migration, and tube formation 
of endothelial cells (130). Major signaling pathways orchestrating 
this process include VEGFR and fibroblastic growth factor recep-
tor (FGFR) signaling pathways and Notch-dependent pathways 
(131–133). As mentioned earlier, extracellular galectin-3 is 
described to act at membrane proteins clusters through lattice 
formation (33, 134), promoting homotypic and heterotypic 
interactions and regulating substratum adhesion and receptor 
dynamics at the plasma membrane (135, 136).
Through its ability to form supramolecular structures 
through multimerization and through binding to glycoproteins 
that display multiple binding sites, galectin-3 serves as a scaffold 
protein that organizes signaling platforms on the cell surface 
of endothelial cells. In this sense, galectin-3 acts a cofactor 
responsible for modulating the angiogenic process, through 
amplification of the signal triggered by its partners in the con-
text of the lattice formed on the cell surface. Galectin-3 binds 
directly on human umbilical vein endothelial cell (HUVEC) 
surface, amplifying the chemotactic response of these cells, 
besides the induction of capillary tube formation in  vitro and 
angiogenesis in  vivo (137). Galectin-3 is also required for the 
stabilization of epithelial–endothelial interaction networks, an 
essential process during angiogenesis (138). In vivo, endothelial 
cells present within tumors are enriched in galectin-3 ligands 
(13). Indeed, optimal vascularization of tumors was observed in 
model systems, where both tumor cells and stromal cells express 
galectin-3 (139). Markowska and  colleagues demonstrated that 
galectin-3 promotes angiogenesis by interacting via CRD with 
complex N-glycans on αvβ3 integrin and through the activation 
of FAK-mediated signaling pathways that influence both VEGF 
and bFGF angiogenic activity. The same group also reported 
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that galectin-3 contributes to the plasma membrane retention of 
VEGFR2, leading to increased angiogenic response to VEGF-A 
(42) (Figure 1C). A similar effect was observed when galectin-3 
was used in combination with galectin-1 and both galectins 
retained VEGFR1 and VEGFR2 on the plasma membrane, 
enhancing endothelial cell growth and tube formation (140).
It is still a matter of debate to what extent the ability of 
galectin-3 to interfere with angiogenesis depends on its post-
translational processing. It is already known that galectin-3 
collagen-like N-terminal domain is susceptible to extracel-
lular cleavage in  vitro and in  vivo by MMP-2 and MMP-9 
(60, 141). Cleaved galectin-3 displays ~20-fold higher affinity for 
endothelial cells (138), incrementing chemotaxis, invasion, and 
homotypic adhesion resulting in increased angiogenesis (142), 
as compared with the intact form of the lectin. The N-terminal 
domain is necessary for optimal oligomerization of galectin-3 
(33, 143); however, it is conceivable that the collagen-like frac-
tion retained after cleavage by MMPs is still sufficient for some 
degree of galectin-3 oligomerization.
Besides its direct role in endothelial cells, galectin-3 also 
influences migration of monocytes/macrophages (144) and their 
activation (145). Tumor-associated macrophages, which express 
galectin-3, have been shown to act in tumor angiogenesis and 
vessel maturation in a density- and phenotype-dependent man-
ner (146, 147). Experiments performed by our group showed 
increased levels of active transforming growth factor β1 (TGFβ1) 
homodimer in galectin-3-expressing tumors (139). TGFβ1 is 
reported to induce chemotaxis and VEGF release by human 
monocytes/macrophages (148, 149). Bone marrow-derived 
macrophages (BMDMs) from galectin-3 KO mice showed a 
reduced basal secretion of VEGF when compared with BMDMs 
from WT mice. Upon TGFβ1 stimulation, WT-BMDMs secreted 
higher amounts of VEGF, as compared with KO-BMDMs (139). 
Galectin-3 targets not only macrophages but also platelets 
(Figure  1C), which release VEGF upon activation through a 
PKC-dependent pathway (150).
In addition to angiogenesis, galectin-3 has also been shown to 
participate in other process required to constitute the tumor vas-
culature, a process named vasculogenic mimicry. This process is 
characterized by the functional plasticity of aggressive tumor cells 
that behave as an endothelial cell in tumor vessels (151, 152). It 
has been proposed that galectin-3 expression in melanoma cells is 
necessary for their ability to form tube-like structures on collagen 
type I matrix. Gene expression signatures of galectin-3 deficient 
cells, as compared to their galectin-3-expressing parental cells, 
indicated co-expression of galectin-3 with a variety of endothelial 
cell markers that are involved in tumor angiogenesis, endothelial 
cell differentiation, and therefore in the process of vasculogenic 
mimicry (153). Understanding the mechanisms underlying this 
phenomenon will be necessary for future interventions.
CONCLUDiNG ReMARKS
Galectin-3 expression is dysregulated in different cancers. Its 
expression varies within different areas of tumors. For example, 
stressing conditions, such as hypoxia and nutrient deprivation, 
induce galectin-3 expression in breast cancer and glioblastoma. 
Under these conditions, accumulation of galectin-3 in the 
cytoplasm favors cell survival. Although the mechanistic details 
of this antiapoptotic activity of galectin-3 are not completely 
understood, there is accumulating evidence that galectin-3 tunes 
the different families of MAPKs. An interesting paradigm for 
galectin-3 function is the formation of nanoclusters with signal-
ing molecules, such as K-RAS. In this context, galectin-3 serves 
as a scaffold protein, favoring the spatial organization of a signal 
transducer partitioned into the plasma membrane, where the 
interaction with other proteins is required for the efficient trans-
duction of cellular signals. Secretion of galectin-3, either active 
through exosomes or other forms of protein release from the 
cytoplasm or passive through cell lysis or increased permeability 
of a dying cell, allows for novel functions of galectin-3, dependent 
on the extracellular ligand (growth factor receptors, integrins, 
and cadherins, among other glycoproteins). On the cell surface, 
the interaction of galectin-3 with glycoproteins illustrates the for-
mation lectin lattices, another example of its scaffold function in 
the organization of supramolecular structures that interfere with 
receptor-triggered signal transduction. Extracellular galectin-3 
is involved with cell migration (tumor cell, endothelial cell, and 
leukocyte migration) and the formation of vessels. At this level, 
secreted galectin-3 plays a homeostatic role in stressed micro-
environments, as it induces formation of vessels that support 
normalization of both oxygen and nutrient delivery to tissues. In 
tumors, such homeostatic role would support tumor progression 
(Figure 1), and therefore it is a natural target for intervention. 
Galectin-3 is also an important modifier of immune cell function, 
which will constitute now another layer of complexity in its roles 
in cancer progression, which will be dealt with in other reviews 
in this series.
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